Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 2 Monate 2 Wochen
@MorphoSys
MorphoSys second quarter 2018, with further advanced
pipeline and a newly established U.S. footprint
https://t.co/FwtqTxnNLX $MPSYF
vor 2 Monate 3 Wochen
@MorphoSys
MorphoSys appointed Jennifer Herron as President of
MorphoSys US Inc. and Executive Vice President, Global Commerci… https://t.co/seSxiqMNt8
vor 2 Monate 4 Wochen
@MorphoSys
MorphoSys increases financial guidance 2018 due to license agreement for
MOR106, currently developed in atopic derm… https://t.co/7L9ZSrMs3L
vor 2 Monate 4 Wochen
@MorphoSys
MorphoSys and @Galapagos announced global license agreement for MOR106
with @Novartis https://t.co/o83q1xOdES $MPSYF
vor 4 Monate 4 Tage
@MorphoSys
Gantenerumab - New Phase 3 Clinical Trials by
MorphoSys’s Partner now Underway https://t.co/D81jBaKgpx $MPSYF
vor 5 Monate 4 Wochen
@MorphoSys
Yesterday, successful 1st trading day @Nasdaq #MorphoSysIPO https://t.co/lPBbaQYrbC
vor 5 Monate 4 Wochen
@MorphoSys
MorphoSys IPO at Nasdaq. First day trading in the U.S. - watch the Bell Ringing Ceremony today at 9.30am EDT (3:30p… https://t.co/lJ6WhNFXBZ
vor 7 Monate 6 Tage
@MorphoSys
MOR208 L-MIND update: results reported today confirm previously reported interim data in r/r DLBCL https://t.co/GbGaSvbRJe $MPSYF
vor 7 Monate 6 Tage
@MorphoSys
MorphoSys presents results for FY2017, guidance fully met, revenues including 1st royalties on Tremfya(R) https://t.co/dosdQbwF1w $MPSYF
vor 8 Monate 1 Tag
@MorphoSys
Ph1 results in atopic dermatitis of IL-17C antibody MOR106 jointly
developed by MOR and GLPG to be presented in lat… https://t.co/RYVDqsZqMK
Medien und Investoren
Corporate Communications und Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
E-Mail Kontakt